17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed systemic mastocytosis
• * Objective evidence of disease, as defined by the following:
• * Hemoglobin \< 10 g/dL
• * Recurrent mast cell mediator-release symptoms that impair the patient's quality of life
• * Symptomatic hepatosplenomegaly
• * Ascites
• * Symptomatic bone disease
• * Profound constitutional symptoms (e.g., fatigue, asthenia, flushing, hyperpyrexia, weight loss, myalgia, and arthralgia)
• * Elevated serum tryptase level
• Mast cell leukemia allowed
• Mastocytosis associated with myeloproliferative disease (e.g., hypereosinophilic syndrome or chronic myelomonocytic leukemia) allowed
• Patients with eosinophilia (i.e., absolute eosinophil count ≥ 1,000/mm\^3) must be evaluated for the presence or absence of FIP1L1-PDGFRA mutation; if the mutation is absent, the patient is eligible; if the mutation is present, the patient is eligible provided disease is refractory to imatinib mesylate
• Patients with indolent disease must have a serum tryptase level ≥ 50 ng/mL OR episodes of anaphylaxis that occur with a frequency of \> 1 per month
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• At least 3 months
• Hematopoietic
• See Disease Characteristics
• Platelet count ≥ 100,000/mm\^3 (\> 25,000/mm\^3 for patients with organomegaly)
• Absolute granulocyte count ≥ 1,500/mm\^3(\> 750/mm\^3 for patients with organomegaly)
• Hepatic
• AST and ALT ≤ 2 times upper limit of normal (ULN) (\< 4 times ULN for patients with hepatomegaly)
• Bilirubin normal
• Alkaline phosphatase ≤ 3 times ULN
• Renal
• Creatinine ≤ 1.4 mg/dL OR
• Creatinine clearance ≥ 60 mL/min
• Cardiovascular
• No New York Heart Association class III-IV congestive heart failure
• No history of myocardial infarction within the past year
• No history of uncontrolled dysrhythmia
• No uncontrolled angina
• No ischemic heart disease within the past 12 months
• No congenital long QT syndrome
• No left bundle branch block
• No serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
• QTc interval \< 450 msec for males or 470 msec for females
• LVEF \> 40% by MUGA
• MUGA or echocardiogram normal
• No prior history of cardiac toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine)
• No cardiac symptoms ≥ grade 2
• No other significant cardiac disease
• Pulmonary
• No symptomatic pulmonary disease requiring medication including any of the following:
• * Dyspnea on or off exertion
• * Paroxysmal nocturnal dyspnea
• * Requirement for oxygen
• * Significant pulmonary disease (e.g., chronic obstructive/restrictive pulmonary disease)
• No home oxygen meeting the Medicare requirement
• No compromised pulmonary status (i.e., DLCO ≤ 80%)
• No prior history of pulmonary toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine)
• No pulmonary symptoms ≥ grade 2
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment
• HIV negative
• No active uncontrolled infection
• No serious medical illness
• No other non-malignant systemic disease
• No history of serious allergic reaction to eggs
• No other malignancy within the past 2 years except dermatological cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• At least 4 weeks since prior chemotherapy
• Endocrine therapy
• Steroids allowed provided tapering to the lowest level possible to treat thrombocytopenia, diarrhea, or malabsorption symptoms of systemic mastocytosis
• Radiotherapy
• At least 4 weeks since prior radiotherapy
• No prior radiation that included the heart in the field (e.g., mantle) or chest
• Surgery
• Not specified
• Other
• At least 4 weeks since prior tyrosine kinase inhibitors
• No concurrent complimentary or alternative medications\* including, but not limited to, the following:
• * Hypericum perforatum (St. John's wort)
• * Milk thistle
• * Kava kava
• * Mistletoe extract
• No concurrent agents that cause QTc prolongation
• No concurrent antiarrhythmic therapy
• No other concurrent investigational therapy NOTE: \*Unless approved by the investigator